Director of Research.
Dr. Chen received graduate and postdoctoral training in prostate cancer and worked as Research Assistant Professor at the University of South Carolina, conducting research on CDK8/19 inhibitor drug discovery and discovering the roles of CDK8/19 in transcriptional reprogramming and prostate cancer. Dr. Chen serves as the Principal Investigator of Phase II SBIR grant from the National Cancer Institute supporting the development of CDK8/19 inhibitors for prostate cancer therapy.
senexbio.com 